Return to search results       New search       Contact for this trial
LCS12 adolescent study
Trial ID: 14371
The study will assess the safety of a sex hormone (levonorgestrel) releasing T-shaped intrauterine contraceptive system in female adolescents under 18 years of age. Approximately 300 generally healthy, post-menarcheal female adolescents with regular menses at the beginning of the study requiring contraception will be enrolled into the study.
Duration of study treatment is approximately 12 months with an option to continue the use of the contraceptive system up to three years if the woman is willing to continue the use after the first 12 months.
The incidence of adverse events over 12 month treatment period will be the main outcome of this study. Also the efficacy (number of pregnancies), discontinuation rate and pharmacokinetics will be evaluated.
Official Title: Multi-center, single-arm study to assess the safety, efficacy, discontinuation rate and pharmacokinetics of the low-dose levonorgestrel intrauterine contraceptive system (LCS12) in post-menarcheal female adolescents under 18 years of age for 1 year, and an optional 2-year extension phase
Product: Skyla (Levonorgestrel, BAY86-5028)
Indication/Disease: Contraception
Trial Status: Completed
Trial Start Date: 2011-09
Trial End Date: 2015-05 (Actual)
Trial Phase: Phase 3
Trial Design:
Trial Type: Interventional
Intervention: Drug
Trial Purpose: Prevention
Trial Endpoint: Safety Study
Allocation: N/A
Blinding: Open Label
Assignment: Single Group Assignment
Trial Arms: 1
Participants: 304
Primary Outcome:
  • Number of adverse events reported by study subjects
    Timeframe: 12 months treatment period
  • Portion of subjects reporting adverse events
    Timeframe: 12 months treatment period
Secondary Outcome:
  • Overall satisfaction rating from 1 to 5 (from very satisfied to very dissatisfied)
    Timeframe: 12 months treatment period
  • Pearl index
    Timeframe: 12 months treatment period
  • Bleeding patterns collected from patients' diary
    Timeframe: 12 months treatment period
  • Concentration of Levonorgestrel in serum
    Timeframe: At 1, 3, 6, 9 or 12 months
  • Concentration of sex hormone binding globulin in serum
    Timeframe: At 1, 3, 6, 9 or 12 months
  • Discontinuation rate
    Timeframe: 12 months treatment period
Eligibility Criteria:
Minimum Age: 12 Years
Maximum Age: 17 Years
Gender: Female
Healthy Volunteers: Yes

Inclusion Criteria:
  • The subject has signed and dated the informed consent form (ICF)
  • The subject is female, generally healthy, post-menarcheal, nulliparous or parous, requiring contraception, and is under 18 years of age at the Screening visit
  • The subject has regular menstrual cycles without hormonal contraceptive use (at regular intervals of 21-35 days)
  • In the opinion of the investigator, the subject has general and uterine conditions suitable for the insertion of levonorgestrel intrauterine contraceptive system (LCS12) (uterine sound depth 6-10 cm)
  • Has clinically normal safety laboratory results
  • The subject has a normal or clinically insignificant cervical smear (i.e. one that does not require further follow up according to Bethesda or a comparable system)
  • The subject is willing and able to attend the scheduled study visits and to comply with the study procedures

Exclusion Criteria:
  • Known or suspected pregnancy or is lactating
  • Vaginal delivery, cesarean delivery, or abortion less than 6 weeks before Visit 1
  • History of ectopic pregnancies
  • Infected abortion or postpartum endometritis less than 3 months before Visit 1
  • Abnormal uterine bleeding of unknown origin
  • Any lower genital tract infection (until successfully treated)
  • Acute or history of recurrent pelvic inflammatory disease
  • Congenital or acquired uterine anomaly
Sponsor: Bayer
Results Synopsis: PDF File
Relevant Links: Click here and search for drug information provided by the FDA.Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.
This information is provided by Bayer under Bayer's disclaimer for publication of clinical trial information.